Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT05267054 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05267054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
April 25, 2022
Completion date
August 30, 2024
Enrollment
53 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

refractory diffuse large b-cell lymphoma, relapsed diffuse large b-cell lymphoma